A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)

  • STATUS
    Recruiting
  • days left to enroll
    84
  • participants needed
    90
  • sponsor
    Altavant Sciences GmbH
Updated on 4 October 2022

Summary

The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.

Description

Rodatristat Ethyl is a peripherally restricted TPH inhibitor being studied as a potential treatment for PAH. This dose-ranging, randomized, double-blind, placebo-controlled, multicenter study will evaluate the effect of Rodatristat Ethyl from baseline on pulmonary vascular resistance as measured at right heart catheterization.

Patients will be enrolled into a main study with an option to enroll into an open label extension.

The study is expected to enroll patients in the USA, Canada and Europe.

Details
Condition Pulmonary Arterial Hypertension
Treatment Placebo, Rodatristat Ethyl 300 mg tablet, Rodatristat Ethyl 600 mg BID, rodatristat ethyl 300 mg tablet BID
Clinical Study IdentifierNCT04712669
SponsorAltavant Sciences GmbH
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male and female 18 years or older 2. Body Mass Index (BMI) >18kg/m2 to <=40kg/m2 3. Symptomatic PAH belonging to one of the following 2018 WHO Clinical Group 1 subtypes
Idiopathic PAH b. Heritable PAH c. Drug- or toxin-induced d. PAH associated with
Connective tissue disease
Congenital systemic to pulmonary shunt (atrial septal defect, ventricular septal defect, patent ductus arteriosus) repaired at least one year prior to Screening
Human immunodeficiency virus (HIV) infection - if diagnosed with HIV, must have stable disease status defined as follows
stable treatment with HIV medications for at least 8 weeks prior to Screening
WHO FC II or III
no active opportunistic infection during the Screening Period
no hospitalizations due to HIV for at least 4 weeks prior to Screening
Confirmed diagnosis of PAH and meet all the following hemodynamic criteria by means of a screening RHC completed prior to randomization
mPAP of >20 mmHg
PVR ≥ 350 dyne•sec/cm5
Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) of ≤ 12 mmHg if PVR ≥ 350 and < 500 dyne•sec/cm5, or PCWP/LVEDP ≤ 15 mmHg if PVR ≥ 500 dyne•sec/cm5
6MWD of 100 to 550 meters at Screening
Currently on a stable treatment regimen with one or more treatments approved for PAH. Stable therapy is defined as receiving the same medication(s) for ≥ 12 weeks prior to the screening RHC and at a stable dose level for each for ≥ 8 weeks prior to the screening RHC (see Protocol Section 6.6.2 for approved PAH medications). Any instances where doses of a medication have been missed prior to RHC must be discussed with the Medical Monitor prior to performing the RHC
Meet all of the following criteria determined by pulmonary function tests completed no more than 24 weeks prior to Screening (performed with or without bronchodilation)
Forced expiratory volume in one second (FEV1) ≥ 60% of predicted normal, and
Total lung capacity (TLC) ≥ 70% of predicted normal or FVC ≥ 70% predicted if TLC is not available; For subjects with CTD associated PAH, if TLC is ≥ 60% of predicted but < 70% of predicted of if FVC ≥ 60% or predicted but < 70% of predicted, high resolution computed tomography [HRCT] obtained within 6 months of screening may be utilized to demonstrate limited interstitial lung disease
If participating in an exercise program for pulmonary rehabilitation, the program must
have been initiated ≥ 12 weeks prior to Screening, and patient must agree to
maintain the current level of rehabilitation for the first 24 weeks of
receiving IP. If not participating in an exercise training program for
pulmonary rehabilitation, patient must agree not to enroll in an exercise
training program for pulmonary rehabilitation during the Screening Period and
the first 24 weeks of receiving IP

Exclusion Criteria

The patient has a history of, or currently has, a constrictive cardiomyopathy
Women of childbearing potential who are pregnant, planning to become pregnant, or lactating or female/male patients unwilling to use effective contraception
WHO pulmonary hypertension (PH) Group 1 PAH associated with portal hypertension or schistosomiasis; PH due to left heart disease (WHO PH Group 2), lung diseases and/or hypoxia (WHO PH Group 3), chronic thromboembolic PH (WHO PH Group 4), or PH with unclear multifactorial mechanisms (WHO PH Group 5)
PH associated with significant venous or capillary involvement (PCWP > 15 mmHg), pulmonary capillary hemangiomatosis, portal hypertension, or unrepaired congenital heart defects (CHD)
Three or more of the following risk factors for left ventricular disease
BMI > 30 kg/m2
Diagnosis of essential hypertension that is actively treated
Diabetes mellitus
History of significant coronary artery disease (e.g., chronic stable angina, history of coronary intervention within the last 3 months, or a stenosis > 70% at coronary angiography)
Atrial fibrillation
Left atrial volume index > 41 mL/m2 [or left atrial diameter (LA) > 4 cm if LAVi unavailable]
Known genetic hypertrophic cardiomyopathy
Known cardiac sarcoidosis or amyloidosis
Known history of any left ventricular ejection fraction (LVEF) < 40% by echocardiogram within 3 years of randomization (Note: a transient decline in LVEF below 40% that occurred and recovered more than 6 months before the start of Screening and was associated with an acute intercurrent condition [e.g., atrial fibrillation] is allowed)
Hemodynamically significant valvular heart disease as determined by the Investigator
including
greater than mild aortic and/or mitral stenosis and/or
severe mitral and/or aortic regurgitation (> Grade 3)
Severe arthritis, musculoskeletal problems, or morbid obesity that, in the opinion of
the Investigator, is the cause of the patient's functional limitation and
would affect the patient's ability to perform or complete the 6MWT
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note